Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Second-line treatment paradigms for diffuse large B-cell lymphomas

(2009) Catherine Thieblemont et al.   Current Oncology Reports

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting

(2008) Christian Gisselbrecht   BRITISH JOURNAL OF HAEMATOLOGY

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study

(2008) A. Martin et al.   HAEMATOLOGICA

Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma

(2008) Kirsty J. Thomson et al.   JOURNAL OF CLINICAL ONCOLOGY

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

(2007) E. Vellenga et al.   BLOOD